title: Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline.
abstract: Since the introduction of clotting factor concentrates, life expectancy of haemophilia patients is increasing and now approaches that of the general male population. Increasingly, haemophilia patients are confronted with age-related co-morbidity, including ischaemic cardiovascular disease. Treatment of stable angina pectoris and the acute coronary syndrome with antithrombotic therapy and percutaneous coronary intervention in haemophilia patients is feasible, but requires a tight co-operation between all specialists involved. As evidence-based guidelines are lacking, we developed a protocol on how we will treat haemophilia patients with ischaemic heart disease.
authors.affiliation: Van Creveldkliniek/Department of Haematology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, Utrecht 3508 GA, The Netherlands. r.schutgens@umcutrecht.nl
authors.forename: R E G
authors.initials: RE
authors.lastname: Schutgens
authors.forename: A
authors.initials: A
authors.lastname: Tuinenburg
authors.forename: G
authors.initials: G
authors.lastname: Roosendaal
authors.forename: S Hoseyni
authors.initials: SH
authors.lastname: Guyomi
authors.forename: E P
authors.initials: EP
authors.lastname: Mauser-Bunschoten
mesh_terms: D054058:Acute Coronary Syndrome / Q000453:epidemiology / Q000235:genetics / Q000601:surgery*; D015906:Angioplasty, Balloon, Coronary; D002985:Clinical Protocols; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006467:Hemophilia A / Q000453:epidemiology / Q000235:genetics / Q000601:surgery*; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000235:genetics / Q000601:surgery*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D015607:Stents
chemical_list: D005343:Fibrinolytic Agents